Abstract
The Transforming Growth Factor-β (TGFβ) superfamily of cytokines is comprised of a number of structurally-related, secreted polypeptides that regulate a multitude of cellular processes including proliferation, differentiation and neoplastic transformation. These growth regulatory molecules induce ligandmediated hetero-oligomerization of distinct type II and type I serine / threonine kinase receptors that transmit signals predominantly through receptor-activated Smad proteins but also induce Smad-independent pathways. Ligands, receptors and intracellular mediators of signaling initiated by members of the TGFβ family are expressed in the mammary gland and disruption of these pathways may contribute to the development and progression of human breast cancer. Since many facets of TGFβ and breast cancer have been recently reviewed in several articles, except for discussion of recent developments on some aspects of TGFβ, the major focus of this review will be on the role of activins, inhibins, BMPs, nodal and MIS-signaling in breast cancer with emphasis on their utility as potential diagnostic, prognostic and therapeutic targets.
Keywords: proteins, hetero-oligomerization
Current Cancer Drug Targets
Title: Transforming Growth Factor-β Superfamily: Evaluation as Breast Cancer Biomarkers and Preventive Agents
Volume: 4 Issue: 2
Author(s): V. Gupta, D. P. Harkin, H. Kawakubo and S. Maheswaran
Affiliation:
Keywords: proteins, hetero-oligomerization
Abstract: The Transforming Growth Factor-β (TGFβ) superfamily of cytokines is comprised of a number of structurally-related, secreted polypeptides that regulate a multitude of cellular processes including proliferation, differentiation and neoplastic transformation. These growth regulatory molecules induce ligandmediated hetero-oligomerization of distinct type II and type I serine / threonine kinase receptors that transmit signals predominantly through receptor-activated Smad proteins but also induce Smad-independent pathways. Ligands, receptors and intracellular mediators of signaling initiated by members of the TGFβ family are expressed in the mammary gland and disruption of these pathways may contribute to the development and progression of human breast cancer. Since many facets of TGFβ and breast cancer have been recently reviewed in several articles, except for discussion of recent developments on some aspects of TGFβ, the major focus of this review will be on the role of activins, inhibins, BMPs, nodal and MIS-signaling in breast cancer with emphasis on their utility as potential diagnostic, prognostic and therapeutic targets.
Export Options
About this article
Cite this article as:
Gupta V., Harkin P. D., Kawakubo H. and Maheswaran S., Transforming Growth Factor-β Superfamily: Evaluation as Breast Cancer Biomarkers and Preventive Agents, Current Cancer Drug Targets 2004; 4 (2) . https://dx.doi.org/10.2174/1568009043481542
DOI https://dx.doi.org/10.2174/1568009043481542 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Differential Role of Apoptosis and Autophagy Associated with Anticancer Effect of Lupulone (Hop β-Acid) Derivatives on Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Ginger and Heart Health: From Mechanisms to Therapeutics
Current Molecular Pharmacology Sanguinarine: A Double-Edged Sword of Anticancer and Carcinogenesis and Its Future Application Prospect
Anti-Cancer Agents in Medicinal Chemistry Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology RNAi in Clinical Studies
Current Medicinal Chemistry Mechanisms of Activation and Key Roles of SGK3 Under Physiological Conditions and in Prostate and Breast Cancer
Current Signal Transduction Therapy Phytoestrogens and other Botanicals: On the Problems of Evidence-based Evaluation
Recent Patents on Cardiovascular Drug Discovery Deep Inspiration Breath-hold (DIBH) Technique to Reduce Cardiac Radiation Dose in the Management of Breast Cancer
Current Cancer Therapy Reviews Targeting RhoA/Rho Kinase and p21-Activated Kinase Signaling to Prevent Cancer Development and Progression
Recent Patents on Anti-Cancer Drug Discovery Caveolin Involvement and Modulation in Breast Cancer
Mini-Reviews in Medicinal Chemistry Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Current Pharmaceutical Design Mechanical Imaging - a Technology for 3-D Visualization and Characterization of Soft Tissue Abnormalities: A Review
Current Medical Imaging Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs)
Current Medicinal Chemistry Identification and Characterization of SNP Mutation in Genes Related to Non-small Cell Lung Cancer
Current Signal Transduction Therapy Regulation of Gene Expression by Progesterone in Cancer Cells: Effects on Cyclin D1, EGFR and VEGF
Mini-Reviews in Medicinal Chemistry Current Strategies for the Treatment of Ulcerative Colitis
Recent Patents on Inflammation & Allergy Drug Discovery The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine Prediction of Cancer Rescue p53 Mutants In Silico Using Naïve Bayes Learning Methodology
Protein & Peptide Letters Minocycline Inhibits mTOR Signaling Activation and Alleviates Behavioral Deficits in the Wistar Rats with Acute Ischemia stroke
CNS & Neurological Disorders - Drug Targets